• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.

作者信息

Shi Yujie, Li Jian, Zhang Lu

机构信息

Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.

出版信息

Ann Hematol. 2022 Nov;101(11):2529-2531. doi: 10.1007/s00277-022-04926-4. Epub 2022 Aug 4.

DOI:10.1007/s00277-022-04926-4
PMID:35927344
Abstract
摘要

相似文献

1
Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.达雷妥尤单抗治疗难治性特发性多中心Castleman病：一例报告
Ann Hematol. 2022 Nov;101(11):2529-2531. doi: 10.1007/s00277-022-04926-4. Epub 2022 Aug 4.
2
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.新诊断和先前接受过治疗的多中心Castleman病对司妥昔单抗的反应相同。
Br J Haematol. 2021 Jan;192(1):e28-e31. doi: 10.1111/bjh.17177. Epub 2020 Oct 31.
3
Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report.芦可替尼治疗难治性特发性多中心Castleman病：一例报告
Turk J Haematol. 2024 Mar 1;41(1):61-63. doi: 10.4274/tjh.galenos.2024.2023.0477. Epub 2024 Feb 15.
4
Siltuximab for Multicentric Castleman Disease-Letter.关于司妥昔单抗治疗多中心Castleman病的信函。
Clin Cancer Res. 2015 Oct 15;21(20):4740. doi: 10.1158/1078-0432.CCR-15-1310.
5
Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation.西妥昔单抗治疗特发性多中心Castleman病的疗效，波兰首例长期观察的真实世界经验。
Leuk Lymphoma. 2021 Dec;62(12):3031-3034. doi: 10.1080/10428194.2021.1941926. Epub 2021 Jun 23.
6
Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.特发性多中心 Castleman 病伴 TAFRO 临床亚型对 IL-6/JAK 抑制有反应：儿科病例系列。
Pediatr Blood Cancer. 2021 Oct;68(10):e29261. doi: 10.1002/pbc.29261. Epub 2021 Jul 24.
7
Brief communication: rituximab in HIV-associated multicentric Castleman disease.简短通讯：利妥昔单抗治疗HIV相关多中心Castleman病
Ann Intern Med. 2007 Dec 18;147(12):836-9. doi: 10.7326/0003-4819-147-12-200712180-00003.
8
[Relapsed/refractory idiopathic multicentric Castleman disease successfully treated with sirolimus: a case report].[西罗莫司成功治疗复发/难治性特发性多中心Castleman病：一例报告]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):513. doi: 10.3760/cma.j.cn121090-20240119-00034.
9
A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.一例托珠单抗难治性特发性多中心 Castleman 病患者成功接受西罗莫司治疗。
Clin Immunol. 2021 Dec;233:108887. doi: 10.1016/j.clim.2021.108887. Epub 2021 Nov 16.
10
Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease.在一名HIV阴性、HHV-8阳性的多中心Castleman病患者中，联合化疗免疫疗法（R-CVP）后序贯利妥昔单抗维持治疗实现完全缓解和病毒学应答。
Leuk Lymphoma. 2008 Nov;49(11):2224-6. doi: 10.1080/10428190802389835.

本文引用的文献

1
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.一项关于硼替佐米、环磷酰胺和地塞米松用于复发/难治性免疫性疾病相关的多中心前瞻性研究。 （这里“iMCD”推测为免疫性疾病相关，原文未明确全称，具体翻译可根据实际全称调整）
Leuk Lymphoma. 2022 Mar;63(3):618-626. doi: 10.1080/10428194.2021.1999437. Epub 2022 Jan 31.
2
Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide.TAFRO 综合征导致的中国患者急性肾损伤：长期应用皮质激素联合硼替佐米和环磷酰胺的疗效。
Kidney Blood Press Res. 2020;45(4):623-630. doi: 10.1159/000505458. Epub 2020 Jun 3.
3
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
4
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.利妥昔单抗联合治疗方案治疗特发性多中心 Castleman 病的疗效。
Ann Hematol. 2018 Sep;97(9):1641-1647. doi: 10.1007/s00277-018-3347-0. Epub 2018 May 7.
5
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.HHV-8阴性/特发性多中心Castleman病的国际循证共识诊断标准。
Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.